Advertisement

Topics

BioXcel Therapeutics Announces Closing of Initial Public Offering

17:01 EDT 12 Mar 2018 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
BRANFORD, Conn., March 12, 2018 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BTI") (Nasdaq:BTAI), a clinical stage biopharmaceutical development company utilizing novel artificial intelligence to identify the next wave of medicines acro...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "BioXcel Therapeutics Announces Closing of Initial Public Offering"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...